Figure 5.
K284-3046 blunted the inhibitory effect of VSIG3 on activated PBMCs and improved the inhibitory effect of VSIG3 on the proliferation of PBMCs. (A) A total of 1×105 PBMCs were incubated with an immobilized anti-human CD3 antibody (1 μg/mL) and human VSIG3 at 10 μg/mL, and compound K204-3046 was added as indicated. The levels of IFN-γ and IL-17 in the cell culture supernatants were measured at 48 h using ELISA kits. ns: not significant, **p<0.01 and ***p<0.001 vs. control. (B) A total of 1×105 CFSE-labeled PBMCs were stimulated with plate-bound anti-human CD3 (1 μg/mL) together with co-absorbed human VSIG3 protein at 10 μg/mL, and compound K204-3046 was added at 10 μM. The proliferation levels of PBMCs were measured. Representative results from three independent experiments are shown.